Effect of fluconazole on human polymorphonuclear leucocyte functions ex vivo against Candida albicans

U S Gürer1, A Cevikbaş, C Johansson

  • 1Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Marmara, Haydarpaşa, Istanbul, Turkey.

Chemotherapy
|July 8, 1999
PubMed

Insights

Fluconazole enhances polymorphonuclear leucocyte (PMN) adherence and intracellular killing of Candida albicans. This antifungal medication did not affect PMN chemotaxis or superoxide anion generation in healthy volunteers.

Area of Science:

  • Mycology
  • Immunology
  • Pharmacology

Background:

  • Polymorphonuclear leucocytes (PMNs) are crucial for host defense against fungal infections.
  • Understanding the impact of antifungal agents on immune cell function is vital for optimizing treatment strategies.

Purpose of the Study:

  • To evaluate the ex vivo effects of a single oral dose of fluconazole (300 mg) on human PMN functions.
  • To assess fluconazole's impact on PMN chemotaxis, adherence, superoxide anion generation, and intracellular killing of Candida albicans.

Main Methods:

  • Healthy volunteers received oral fluconazole (300 mg).
  • Ex vivo analysis of PMN chemotaxis (zymosan-activated serum), adherence, and superoxide anion (O-2) generation.
  • Intracellular killing of Candida albicans blastoconidia by PMNs was assessed using viable colony counts.

Main Results:

  • Fluconazole did not alter PMN chemotaxis or O-2 generation.
  • Significant enhancement of PMN adherence was observed ex vivo.
  • In vitro, therapeutic concentrations of fluconazole significantly increased intracellular killing of C. albicans by PMNs at 30 minutes compared to ex vivo conditions.

Conclusions:

  • Fluconazole administration enhances PMN adherence and improves the intracellular killing capacity against Candida albicans, particularly in vitro.
  • These findings suggest that fluconazole may augment host immune responses against fungal pathogens.